Jonathan Doughty is a global thought leader, consultant, speaker, moderator and C-suite executive in the foodservice and leisure sectors working around the world in retail, transit and leisure. In this month’s column, he discusses how the restaurant industry is entering a new phase.
The rise of GLP-1 medications such as Ozempic, Wegovy and Mounjaro is beginning to reshape the restaurant industry in ways few operators could have predicted five years ago. Originally developed to treat Type 2 diabetes and obesity, these appetite-suppressing drugs are now being used by millions of consumers globally, fundamentally changing eating habits, dining behaviours and expectations around food.
For restaurateurs, this is more than a passing health trend. GLP-1 medicines reduce appetite, slow digestion and often change the emotional relationship consumers have with food. Guests are eating less, ordering differently and becoming more selective about what they consume. While restaurants have always adapted to changing consumer preferences, the scale and speed of GLP-1 adoption mean the industry is entering a new phase where volume-based dining models may no longer be enough. This is critical as so much of the foodservice world is based on this key principle.
Here are five major changes restaurant operators need to understand, as they will have little or no visibility on who is taking the drugs, what stage they are at in the treatment and few outward signs of self-administration.
1. Portion Sizes Are Becoming Too Large
One of the most immediate impacts of GLP-1 medications is a dramatic reduction in appetite. Many users report feeling full after only a few bites, meaning traditional portion sizes can suddenly feel excessive.
For restaurants, oversized plates now risk creating waste rather than value. The old assumption that larger portions equal better value is beginning to weaken, especially among health-conscious consumers.
This shift creates both challenges and opportunities. Restaurants that continue serving oversized dishes may see lower satisfaction scores and increased food waste. On the other hand, operators that introduce flexible portioning can improve margins while appealing to changing consumer habits.
2. Consumers Are Prioritising Nutritional Density
GLP-1 users tend to become far more conscious about what they eat because they physically consume less food overall. When appetite is reduced, every bite matters more.
As a result, nutritional density is becoming increasingly important. Guests are seeking meals that provide protein, fibre, vitamins and sustained energy rather than simply calories.
Protein has become particularly important. Many GLP-1 users actively focus on maintaining muscle mass during weight loss, driving demand for lean meats, fish, eggs, legumes and high-protein menu options.
Restaurants that clearly communicate nutritional benefits are likely to gain an advantage. Menus featuring calorie transparency, protein counts or ingredient sourcing increasingly align with consumer expectations, but also need to be communicated in a discrete way.
This does not mean indulgence disappears entirely. Consumers still want enjoyment and experience when dining out. However, the balance is shifting from “quantity and indulgence” toward “quality and wellbeing”.
3. Fewer Courses and Lower Average Spend
GLP-1 medicines are also changing how consumers structure meals when dining out. Diners who previously ordered starters, mains and desserts may now stop after a single course or share dishes across the table.
Alcohol consumption may also decline. Many users report reduced interest in alcohol while taking GLP-1 drugs, partly because these medicines influence reward pathways in the brain. This presents a particular challenge for restaurants that rely heavily on beverage margins.
The result could be a gradual reduction in average spend per guest unless operators adapt their offering. Restaurants may need to rethink pricing structures, upselling strategies and menu architecture.
Rather than focusing on volume consumption, businesses may need to emphasise premiumisation and experience. High-quality ingredients, exceptional service and memorable atmosphere become even more important when customers order less food overall.
4. Menu Variety Must Become More Flexible
GLP-1 users often experience changing food preferences and sensitivities. Rich foods may suddenly feel too heavy, while lighter dishes become more attractive. Consumers also tend to become less impulsive and more intentional about their choices.
This means menus need greater flexibility. Restaurants that only offer large, heavy or highly indulgent dishes may struggle to meet evolving demand.
Lighter preparations, vegetable-forward dishes, grilled proteins, soups, salads and customisable meals are becoming increasingly relevant across all dining segments, not just traditionally healthy brands.
Importantly, restaurants should avoid treating this purely as a “diet trend”. GLP-1 adoption spans multiple demographics, including affluent consumers, business professionals and middle-aged diners who remain highly active restaurant users. Users are not obvious, visible or identifiable.
5. Hospitality and Experience Matter More Than Ever
Perhaps the most important shift is psychological. As consumers eat less, restaurants become less about consumption and more about experience, connection and atmosphere.
If diners are ordering fewer dishes, they still need a reason to visit restaurants rather than simply eating at home. Hospitality, storytelling, ambience and social interaction therefore become more valuable competitive advantages.
Restaurants that focus purely on food volume may struggle. Those that create memorable experiences can still thrive even if guests consume fewer calories overall.
This is particularly relevant for premium casual and fine dining concepts. Consumers may dine out less frequently, but when they do, they may prioritise quality, environment and emotional value over quantity. It is also relevant around the world as consumers struggle with the impact of increasingly high calorific food which is easy to access 24/7.
Ultimately, the restaurant industry is unlikely to shrink because of GLP-1 drugs, but it will evolve. The businesses that succeed will be those that recognise dining is becoming more intentional, health-aware and experience-driven and that is a good thing.
For restaurateurs, the key lesson is clear: the future guest may eat less, but their expectations will be higher than ever.
